The RITUXAN for RA EXPERIENCE Program

 

through Genentech
Rheumatology
Access Solutions

$4,000 per
12-month period
toward the cost of
Rituxan for eligible patients

Learn More

Indication

Rituxan® (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Rituxan is not recommended for treatment of patients with severe active infections.

Important Safety Information

RITUXAN administration can result in serious, including fatal, adverse reactions. These include: infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, and progressive multifocal leukoencephalopathy (PML).

Warnings and Precautions

Rituxan administration can also result in additional serious, including fatal, adverse reactions including:

  • hepatitis B reactivation
  • other infections including bacterial, fungal, new or reactivated viral infections
  • cardiovascular events

Patients should be closely observed for signs of infection if biologic agents and /or DMARDs other than methotrexate are used concomitantly

Common adverse reactions include infusion reactions and infections

For additional safety information, please see the full prescribing information, including BOXED WARNINGS and Medication Guide.

Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN infusion.

Print Page
 

Dedicated to patient access

Providing a broad range of programs to meet the diverse needs of your patients

Access Solutions

Please visit RheumatologyAccessSolutions.com or contact Genentech Rheumatology Access Solutions at 1-866-681-3261 for complete program terms and eligibility requirements.

Genentech Rheumatology Access Support

 

Coverage & Reimbursement

From benefits investigation to assistance with appeals and denials, Genentech Rheumatology Access Solutions helps your office resolve coverage- and reimbursement-related issues:

  • Benefit investigations
  • Prior authorization and recertification assistance
  • Help with appeals
  • Answers to questions about billing

Informational Resources

Genetech Rheumatology Access Solutions provides additional services and information that may be of assistance to you if Rituxan for RA has been prescribed for one of your patients:

  • Glossary of access and reimbursement terms
  • Product spoilage and return information
  • Helpful online tutorials and Medicare/Medicaid search tools
  • Communication assistance services (translations, telephone-to-typewriter services)

Genentech Rheumatology Access Solutions helps to resolve specific access and reimbursement issues for individual patients every day. Our dedicated specialists help bring patient treatment and practice solutions together.

Rituxan and its logo are trademarks of Biogen Idec Inc. The Access Solutions logo and the Access Solutions Treatment made possible logo are trademarks of Genentech USA, Inc.